Promis Neurosciences Inc PMN

$9.15 +0.03 (0.33%)

Valuation

Market cap
82,593,000
Revenue TTM
$0
Net income TTM
$-39,720,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
35,262
Avg volume
40,264
Day's range
$8.78 – $9.37
Shares out
8,968,000
Stochastic %K
11%
Beta
-0.26
Analysts
Strong Sell
Price target
$43.50

Price

Company profile

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic ol...

Show more

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
416 847 6898
Website
https://www.promisneurosciences.com
Address
1920 Yonge Street, Suite 200, Toronto, Canada

Latest news

Stocktwits

Blueknoser Oct 7, 3:56 PM
$PMN AI overview: • Late 2024 to Late 2026 — Phase 1b 12-Month Treatment Completion: Dosing for all patients in the 12-month trial is on track to conclude by the end of 2026. • Q1 2027 — Unblinded Phase 1b Top-line Data Readout: This represents the single largest catalyst for the program. The unblinded 12-month package is expected to deliver definitive safety profiles, a broad biomarker package, and—for the first time—preliminary cognitive outcome measures. • 2027 — FDA Alignment & Potential Phase 3 Path: Following compilation of the full Phase 1b dataset, the company plans to utilize its Fast Track status to hold an official FDA meeting. If the top-line results are favorable, ProMIS aims to advance PMN310 directly into a single registration/Phase 3 study. • Subcutaneous Formulation Development: In parallel with clinical progression, the company is continuing to advance a subcutaneous version of PMN310 paired with an auto-injector device for more convenient patient administration.
0 replies
Blueknoser Oct 7, 11:36 AM
$PMN Perhaps Biogen is planning a buyout of Promis? They have about a billion and a half in loose change kicking around; they may need a partner! Things are really looking good: "During her time at Biogen and F. Hoffmann-La Roche, Dr. Rubino led and helped shape Alzheimer’s disease programs across late-stage development, scientific and medical strategy, market preparation and commercialization planning. Her experience includes global leadership supporting the LEQEMBI® franchise, preparation for next-generation Alzheimer’s therapies, and the build-out of large global medical organizations across the United States, Europe and other major markets. She also held senior global leadership roles across multiple sclerosis, spinal muscular atrophy and neuropsychiatry." Promis' PMN310, for all intents and purposes, seems to be superior to the 2 leading drugs, (Leqembi & Kisunla)! Wow!!
0 replies
gruccione Oct 6, 9:25 PM
$PMN FYI
0 replies
Blueknoser Oct 6, 3:56 PM
$PMN New CCO has a most impressive resume!
0 replies
ToeJoe Oct 6, 2:33 PM
$PMN COVERUP.
0 replies
GoforProMIS Oct 6, 1:08 PM
$PMN bold statement to hire CCO from big competitor like $BIIB and $RHHBY to a small Phase 1b Company Dr. Ivana Rubino must have huge positive faith for the data readout in January 27? She saw more and knows more than all other how to proceed and make PMN310 Precise AD a success! Good luck we are on the right path!
2 replies
Blueknoser Oct 6, 12:05 PM
$PMN
0 replies
Blueknoser Oct 6, 11:47 AM
$PMN “Neuroscience has been at the center of my career, and I have had the privilege of working across several areas in which major scientific advances have transformed what is possible for patients,” said Dr. Rubino. “Alzheimer’s disease is perhaps one of the clearest examples: although we have made significant progress, meaningful scientific, clinical and access challenges remain. What attracted me to ProMIS was both the differentiated science behind PMN310 and the broader potential of the company’s approach to targeting toxic misfolded proteins. If the clinical data in the ongoing Alzheimer’s trial continue to be supportive, PMN310 could represent an important next step in Alzheimer’s treatment. I am excited to help translate the science into development and commercial strategies that can ultimately create meaningful value for patients, families and the neuroscience community.” Awesome
0 replies